Clinical Research Directory
Browse clinical research sites, groups, and studies.
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Sponsor: Daiichi Sankyo
Summary
Trastuzumab deruxtecan (T-DXd) is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of T-DXd used in Chinese lung cancer patients with HER2 mutations. This real world, prospective study will assess the effectiveness and safety of T-DXd in patients with locally advanced or metastatic, HER2 mutation-positive NSCLC in real-world setting.
Official title: Clinical Effectiveness and Safety of Trastuzumab Deruxtecan in Chinese Patients With HER2 Mutant Metastatic Non-small Cell Lung Cancer: a Prospective, Observational Study (RERUN)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
150
Start Date
2025-02-21
Completion Date
2027-02-12
Last Updated
2025-05-28
Healthy Volunteers
No
Conditions
Interventions
No drug
This is an non-interventional, observational study. No drug will be provided or administered as part of this protocol; however, participants on T-DXd will be enrolled in this study.
Locations (23)
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, China
Peking University International Hospital
Beijing, China
Beijing Cancer Hospital
Beijing, China
Hunan Second People's Hospital
Changsha, China
Fujian Cancer Hospital
Fuzhou, China
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, China
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
Zhejiang Cancer Hospital
Hangzhou, China
Anhui Provincial Cancer Hospital
Hefei, China
First Affiliated Hospital of Shandong First Medical University
Jinan, China
Cancer Hospital of Shandong First Medical University
Jinan, China
The First Affiliated Hospital of Jinzhou Medical University
Jinzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
Guangxi Medical University Cancer Hospital
Nanning, China
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, China
Zhongshan Hospital Fudan University
Shanghai, China
The First Hospital of China Medical University
Shenyang, China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, China
The Fourth Hospital of Hebei Medical University
Shijiazhuang, China
Shangxi Provincial Cancer Hospital
Taiyuan, China
The First Affiliated Hospital of Xiamen University
Xiamen, China
Henan Cancer Hospital
Zhengzhou, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China